Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment
| Autor: | Dalibor Valík, Regina Demlová, Lenka Zdrazilova-Dubska, Beatrix Bencsiková, Katerina Pilatova |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment Immunology Antineoplastic Agents Neutropenia Granulocyte Granulopoiesis 03 medical and health sciences 0302 clinical medicine Neoplasms Granulocyte Colony-Stimulating Factor Immune Tolerance Animals Humans Immunology and Allergy Medicine business.industry Myeloid-Derived Suppressor Cells Cancer medicine.disease Granulocyte colony-stimulating factor Cell Transformation Neoplastic 030104 developmental biology medicine.anatomical_structure Cytokine Oncology 030220 oncology & carcinogenesis Cancer research Myeloid-derived Suppressor Cell business Febrile neutropenia |
| Zdroj: | Cancer Immunology, Immunotherapy. 67:1919-1929 |
| ISSN: | 1432-0851 0340-7004 |
| Popis: | Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF (rhG-CSF) has become the main therapeutic agent for the treatment of neutropenia and prophylaxis of febrile neutropenia in cancer patients. However, we show here that rhG-CSF triggers accumulation of granulocytic and monocytic subsets. Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink